abstract |
Part of the present invention is based on the discovery of a group of binding proteins that specifically bind HGF, particularly human HGF. These binding proteins are antibody systems as long as they contain the CDR-based antigen (ie, HGF) binding sites of a group of antibodies that specifically bind HGF. The present application provides a group of binding proteins that bind hepatocyte growth factor (HGF), particularly human HGF, and neutralize its activity. These binding proteins can be used as diagnostic agents and / or therapeutic agents. In terms of therapeutic activity, these binding proteins can be used to treat certain HGF-responsive diseases, such as certain HGF-responsive tumors. |